Hikal Ltd. — Investor Relations & Filings
Hikal Ltd. provides solutions across the life sciences value chain, specializing in the development and manufacturing of active ingredients, intermediates, and formulations. The company operates through two primary business segments: Pharmaceuticals and Crop Protection. In the pharmaceutical division, it focuses on the production of Active Pharmaceutical Ingredients (APIs) and advanced intermediates for various therapeutic areas. The crop protection segment involves the contract manufacturing of pesticides, herbicides, and fungicides for global agrochemical leaders. Hikal offers comprehensive Contract Research and Manufacturing Services (CRAMS), leveraging its research and development capabilities to support clients from early-stage development to commercial-scale production. Its facilities adhere to international quality standards, maintaining a strong track record of regulatory compliance with global health authorities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Retirement | 2026-04-14 | English | |
| Reply to Clarification- Financial results | 2026-04-13 | English | |
| Copy of Newspaper Publication | 2026-04-10 | English | |
| Disclosure under SEBI Takeover Regulations | 2026-04-08 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-07 | English | |
| Trading Window | 2026-03-25 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42181937 | Retirement | 2026-04-14 | English | ||
| 42189745 | Reply to Clarification- Financial results | 2026-04-13 | English | ||
| 42201768 | Copy of Newspaper Publication | 2026-04-10 | English | ||
| 42176029 | Disclosure under SEBI Takeover Regulations | 2026-04-08 | English | ||
| 42196992 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-07 | English | ||
| 42177982 | Trading Window | 2026-03-25 | English | ||
| 42173827 | Updates | 2026-02-18 | English | ||
| 42174477 | Disclosure under SEBI Takeover Regulations | 2026-02-18 | English | ||
| 42174934 | General Updates | 2026-02-18 | English | ||
| 42180638 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-17 | English | ||
| 42174247 | Updates | 2026-02-12 | English | ||
| 42196235 | Copy of Newspaper Publication | 2026-02-12 | English | ||
| 42200516 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-11 | English | ||
| 42209032 | Updates | 2026-02-11 | English | ||
| 42209982 | Record Date | 2026-02-11 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ArriVent BioPharma, Inc.
Clinical-stage biopharma developing oncology drugs for diff…
|
AVBP | US | Manufacturing |
|
ARROWHEAD PHARMACEUTICALS, INC.
Biotechnology company developing RNAi therapies to treat in…
|
ARWR | US | Manufacturing |
|
ARS Pharmaceuticals, Inc.
Develops and commercializes needle-free products for admini…
|
SPRY | US | Manufacturing |
|
ARTELO BIOSCIENCES, INC.
Clinical-stage biopharma developing therapeutics by modulat…
|
ARTL | US | Manufacturing |
|
Arura Pharma Inc
Diversified manufacturer and distributor in consumer goods …
|
— | CA | Manufacturing |
|
Ascelia Pharma
Biotechnology company developing and commercializing novel …
|
ACE | SE | Manufacturing |
|
Ascendis Pharma A/S
Biopharmaceutical firm using its prodrug technology to trea…
|
ASND | DK | Manufacturing |
|
Ascentage Pharma Group International
Integrated biopharma developing novel small molecule therap…
|
6855 | HK | Manufacturing |
|
ASCENTAGE PHARMA GROUP INTERNATIONAL
A clinical-stage biopharma developing novel therapies for c…
|
AAPG | US | Manufacturing |
|
Ascletis Pharma Inc.
R&D driven biotech developing best-in-class therapeutics, p…
|
1672 | KY | Manufacturing |
Hikal Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61437/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61437 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61437 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61437 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61437}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Hikal Ltd. (id: 61437)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.